{ 120件 }
Izumihara R, Nomoto H*, Kito K, Yamauchi Y, Omori K, Shibayama Y, Yanagiya S, Miya A, Kameda H, Cho KY, Nagai S, Sakuma I, Nakamura A, Atsumi T.
Switching from conventional fibrates to pemafibrate has beneficial effects on the renal function of diabetic subjects with chronic kidney disease.
Diabetes Metab J, in press.
IF: 5.9, 5-Y IF: 5.4
Sho Furusawa, Hiroshi Nomoto, Hiroki Yokoyama, Yuka Suzuki, Atsushi Tsuzuki, Kiyohiko Takahashi, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, So Nagai, Shinji Taneda, Yoshio Kurihara, Akinobu Nakamura, Tatsuya Atsumi.
Glycemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: a multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study) Diabetes, Obesity and Metabolism, in press
IF=5.8
Akinobu Nakamura, Aika Miya, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, So Nagai, Tatsuya Atsumi.
Positive association between proinsulin and fatty liver index in people with type 2 diabetes.
Endocr J, in press.
IF: 2.0
Nomoto H, Kito K, Iesaka H, Handa T, Yanagiya S, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Sakuma I, Nakamura A, Atsumi T.
Preferable Effects Of Pemafibrate On Liver Function And Fibrosis In Subjects With Type 2 Diabetes Complicated With Liver Damage Diabetol Metab Syndr, in press IF= 4.7
Sekizaki T, Kameda H, Nakamura A, Kuwabara S, Nomoto H, Cho KY, Ishi Y, Motegi H, Miyoshi H, Atsumi T.
Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas Pituitary, in press IF = 3.8
Nomoto H, Takahashi Y, Takano Y, Yokoyama H, Tsuchida K, Nagai S, Miya A, Kameda H, Cho KY, Nakamura A, Atsumi T.
Effect of switching to once-weekly semaglutide on non-alcoholic fatty liver disease: The SWITCH-SEMA 1 subanalysis Pharmaceutics, in press IF = 5.4, 5-Y IF= 6.0
第96回日本内分泌学会学術集会 愛・内分泌賞 大江 悠希先生
Favorable effect of pemafibrate on insulin resistance and β-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Yuki Oe, Shinichiro Kawata, Kazuhisa Tsuchida, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Ichiro Sakuma, Naoki Manda, Akinobu Nakamura, Tatsuya Atsumi Pharmaceutics, in press IF 6.525
アメリカ内分泌学会（ENDO 2023）Outstanding Abstract Award 桑原 咲先生